FDA "Blue Ribbon" Panel
Formula, Inc., an advocacy group involved in issues arising from the Syntex infant formula recall in 1979, is asking HHS Secretary Sullivan to remove Syntex President Paul Frieman from the panel because of his relationship to the infant formula situation as president of Syntex Labs when the recall was conducted. Syntex notes that the government chose not to prosecute the company or any executives as a followup to the situation.
You may also be interested in...
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.